- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04811469
Safety, Tolerability and Pharmacokinetics of CBP-174 in Healthy Adults
A Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of CBP-174 After Oral Administration
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Victoria
-
Melbourne, Victoria, Australia, 3004
- Nucleus Network Pty Ltd
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects will be enrolled into the study only if they meet ALL of the following inclusion criteria:
- Subjects are fully informed of the study, and are willing to participate in the study and sign the informed consent document prior to any procedure
- Healthy male and female subjects, aged 18 to 55 years (both inclusive)
- Body mass index is between 18 and 32 kg/m2 (both inclusive), the weight of male subjects ≥ 50 kg, the weight of female subjects ≥ 45 kg
- Considered generally normal or abnormal with no clinical significance upon medical history, physical examination, vital signs, ECG, and clinical laboratory tests, as judged by the Investigator
- Female subjects of child-bearing potential must agree to use highly effective contraceptive methods 1 month before the screening, during the entire study, and within 3 months after the end of this study, and have no egg donation plan within 3 months of study end. The male partner of a female subject must agree to use condoms during the screening, entire study, and within 3 months after the end of this study. Male subjects considered fertile must agree to not plan to father a child, donate sperm, and take effective contraceptive methods during the screening, entire study, and within 3 months after the end of this study. The female partner of male subjects must agree to use a highly effective method of female contraception (Section 9.8.3.2) during the screening, entire study, and within 3 months after the end of this study. Contraceptive requirements applies to subjects in same sex relationships for male and female subjects, female subjects of non child bearing potential or male subjects with female partners of non-childbearing potential.
- Subjects who are able to communicate well with Investigators, as well as understand and adhere to the requirements of this study
Exclusion Criteria:
Subjects will be excluded from the study, if they meet ANY of the following criteria:
Subjects will be excluded from the study, if they meet ANY of the following criteria:
- Subjects who have difficulties in venous blood collection or history of dizziness with blood or needles
- Female subjects who have a positive pregnancy test or are breastfeeding
- Subjects who have allergy/hypersensitivity history to any excipient of CBP-174 solution, or hypersensitivity to antihistamines, or severe allergies at the discretion of Investigator
- Exposure to any other investigational medicinal product or any other clinical trial within 30 days or 5 times half-lives (whichever is longer) before dosing current study medication
- Subjects who have a history of gastrointestinal (such as duodenal ulcer, alimentary tract hemorrhage, etc.), liver or kidney disease, or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs
- Subjects who have a history of significant eye diseases (such as keratitis, and scleritis, etc.) or clinical significant eye signs (conjunctiva hyperemia, etc.)
- Subjects who have a history of attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD)
Subjects who have a history of sleep disorders within 2 years before the screening visit or score highly on the PSQI or ISI questionaire; or have a history of epilepsy or other seizure disorder
*Pittsburgh Sleep Quality Index (PSQI) ≥ 8 or Insomnia Severity Index (ISI) ≥ 8
- Subjects who have the medical history of other significant diseases (including but not limited to pulmonary, cardiovascular, gastrointestinal, hematological endocrinological, immunological, dermatological, malignant diseases, mental and nervous systems, and other related diseases) or any other disease/ailment at the discretion of the Investigator
Subjects with any of the following clinical laboratory tests results at screening:
a Aspartate aminotransferase (AST) > 1.5 × the upper limit of normal (ULN)
b Alanine aminotransferase (ALT) > 1.5 × ULN
c Serum creatinine > 1.2 × ULN; or creatinine clearance < 60 mL/min (calculated by the Cockcroft-Gault)
*The clinical laboratory tests of hematology, blood biochemistry, or urinalysis could be allowed repeat once if Investigator considers it necessary
- Subjects whose QTcF interval prolongation at screening (male: QTcF interval ≥ 450 ms, female: QTcF interval ≥ 470 ms)
- Blood donation or blood loss more than 400 mL within 3 months before the screening visit
- Subjects with a known history of drug abuse within 2 years before the screening visit; or positive drug abuse at screening
- Weekly alcohol consumption of more than 14 units of alcohol (1 unit of alcohol = 360 mL of beer or 45 mL of spirit with the alcohol content of 40% or 150 mL of wine) in any week within the past 3 months before the screening visit; or intake of alcohol-containing products within 48 hours before the first dose, or cannot abstain from any alcohol product during the study, or positive breath alcohol test at screening or check-in (Day -1)
- Smoking history (> 5 cigarettes per day) within 3 months before the screening visit, or cannot abstain from any tobacco products during the study, or positive urine nicotine test before randomization
- Excessive drinking of tea, coffee, or caffeine-containing beverage (at least 8 cups per day, 1 cup = 250 mL) any day within 3 months before screening; intake of rich caffeine- or xanthine-containing food or drinks that may produce caffeine or xanthine after being metabolized (eg, coffee, tea, chocolate, cola drinks) within 48 hours before the first dose
- Any marketed medication (prescription and nonprescription drugs) within 14 days before the first dose or within 5 times the elimination half-life or pharmacodynamic half-life of the medication (excluding oral contraceptives and low dose paracetamol at the discretion of the Investigator, or topical ointments at the discretion of the Investigator)
- Administration of a Coronavirus Disease 2019 (COVID-19) vaccine in the past 14 days prior to dosing
- Use of herbal medicines, dietary supplements and vitamin within 14 days before the first dose(permissible at the discretion of the Investigator)
- Subjects who have a major surgery within 3 months before the first dose or who plan to undergo surgery during the study
- Positive screening test for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), or hepatitis C antibody
- Subjects who are determined as not eligible to participate in this study by the Investigator
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CBP-174
CBP-174 oral solution
|
CBP-174 oral solution, given once
|
Experimental: Placebo
placebo oral solution
|
Placebo oral solution, given once
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of adverse events and serious adverse events
Time Frame: Up to 7 days post dosing
|
Adverse events will be coded according to the Medical Dictionary for Regulatory Activities (MedDRA) Dictionary.
|
Up to 7 days post dosing
|
Severity of adverse events and serious adverse events
Time Frame: Up to 7 days post dosing
|
The investigator may use the CTCAE V5.0 to assist in the determination of severity and clinical significance.
|
Up to 7 days post dosing
|
Change in blood pressure
Time Frame: Up to 7 days post dosing
|
Blood pressure measured in mmHg
|
Up to 7 days post dosing
|
Change in pulse rate
Time Frame: Up to 7 days post dosing
|
Pulse rate measured per minute
|
Up to 7 days post dosing
|
Change in respiratory rate
Time Frame: Up to 7 days post dosing
|
respiratory rate measured in breaths per minute
|
Up to 7 days post dosing
|
Change in tympanic temperature
Time Frame: Up to 7 days post dosing
|
tympanic temperature measured in celsius
|
Up to 7 days post dosing
|
Clinically significant abnormality in physical examinations
Time Frame: Up to 7 days post dosing
|
Physical examinations includes examination in cutaneous, lymph node, head (especially of eyes) and neck, chest, abdomen, musculoskeletal and nervous systems.
|
Up to 7 days post dosing
|
Clinically significant change in heart rate
Time Frame: Up to 7 days post dosing
|
Heart rate in beats per minute (Bpm) through 12-lead ECG assessment.
The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
|
Up to 7 days post dosing
|
Clinically significant change in RR interval
Time Frame: Up to 7 days post dosing
|
R-R interval measured in millisecond through 12-lead ECG assessment.
The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
|
Up to 7 days post dosing
|
Clinically significant change in PR interval
Time Frame: Up to 7 days post dosing
|
P-R interval measured in millisecond through 12-lead ECG assessment.
The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
|
Up to 7 days post dosing
|
Clinically significant change in QRS complex
Time Frame: Up to 7 days post dosing
|
QRS complex measured in millisecond through 12-lead ECG assessment.
The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
|
Up to 7 days post dosing
|
Clinically significant change in QT interval
Time Frame: Up to 7 days post dosing
|
QT interval measured in millisecond through 12-lead ECG assessment.
The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
|
Up to 7 days post dosing
|
Clinically significant change in Fridericia's Correction QT (QTcF) interval
Time Frame: Up to 7 days post dosing
|
QTcF interval measured in millisecond through 12-lead ECG assessment.
The Investigator or designee will be responsible for review and interpretation of safety ECGs on site.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Total Protein (TB)
Time Frame: Up to 7 days post dosing
|
Measured in g/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Albumin (ALB)
Time Frame: Up to 7 days post dosing
|
Measured in g/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Alanine aminotransferase (ALT)
Time Frame: Up to 7 days post dosing
|
Measured in IU/L.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Aspartate aminotransferase (AST)
Time Frame: Up to 7 days post dosing
|
Measured in IU/L.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Alkaline phosphatase (ALP/AKP)
Time Frame: Up to 7 days post dosing
|
Measured in IU/L.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Glutamyl transpeptidase
Time Frame: Up to 7 days post dosing
|
Measured in U/L.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Total bilirubin
Time Frame: Up to 7 days post dosing
|
Measured in mg/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Direct Bilirubin
Time Frame: Up to 7 days post dosing
|
Measured in mg/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Indirect Bilirubin
Time Frame: Up to 7 days post dosing
|
Measured in mg/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Blood Glucose
Time Frame: Up to 7 days post dosing
|
Measured in mg/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Blood Urea
Time Frame: Up to 7 days post dosing
|
Measured in mg/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Blood Uric Acid
Time Frame: Up to 7 days post dosing
|
Measured in mg/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Blood Creatinine
Time Frame: Up to 7 days post dosing
|
Measured in mg/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Blood Creatine Kinase
Time Frame: Up to 7 days post dosing
|
Measured in IU/L.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Blood Potassium
Time Frame: Up to 7 days post dosing
|
Measured in mmol/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Blood Sodium
Time Frame: Up to 7 days post dosing
|
Measured in mmol/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Blood Chloride
Time Frame: Up to 7 days post dosing
|
Measured in mmol/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Blood Calcium
Time Frame: Up to 7 days post dosing
|
Measured in mmol/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Blood Total Cholesterol
Time Frame: Up to 7 days post dosing
|
Measured in mmol/L.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal laboratory value in Blood Triglycerides
Time Frame: Up to 7 days post dosing
|
Measured in mmol/L.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Leukocyte Count
Time Frame: Up to 7 days post dosing
|
Counted in K/uL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Neutrophil count
Time Frame: Up to 7 days post dosing
|
Counted in K/uL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Lymphocyte count
Time Frame: Up to 7 days post dosing
|
Counted in K/uL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Monocytes count
Time Frame: Up to 7 days post dosing
|
Counted in K/uL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Eosinophils count
Time Frame: Up to 7 days post dosing
|
Counted in K/uL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Basophil count
Time Frame: Up to 7 days post dosing
|
Counted in K/uL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in percentage of Neutrophil
Time Frame: Up to 7 days post dosing
|
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in percentage of Lymphocyte
Time Frame: Up to 7 days post dosing
|
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in percentage of Monocytes
Time Frame: Up to 7 days post dosing
|
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in percentage of Eosinophils
Time Frame: Up to 7 days post dosing
|
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in percentage of Basophils
Time Frame: Up to 7 days post dosing
|
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Erythrocyte count
Time Frame: Up to 7 days post dosing
|
Counted in K/uL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Hemoglobin
Time Frame: Up to 7 days post dosing
|
Measured in mg/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Hematocrit
Time Frame: Up to 7 days post dosing
|
Measured in %.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Platelets
Time Frame: Up to 7 days post dosing
|
Counted in K/uL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal finding in Urine Occult Blood
Time Frame: Up to 7 days post dosing
|
Urine Occult Blood will be record as positive or negative.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Urine Bilirubin
Time Frame: Up to 7 days post dosing
|
Measured in mg/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Urine pH
Time Frame: Up to 7 days post dosing
|
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Urine Protein
Time Frame: Up to 7 days post dosing
|
Measured in mg/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Urine Glucose
Time Frame: Up to 7 days post dosing
|
Measured in mg/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Urine Specific gravity
Time Frame: Up to 7 days post dosing
|
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Urine Ketones
Time Frame: Up to 7 days post dosing
|
Measured in mg/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Urobilinogen
Time Frame: Up to 7 days post dosing
|
Measured in mg/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Urinary leukocyte
Time Frame: Up to 7 days post dosing
|
Urinary leukocyte will be counted in K/uL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Urine erythrocytes
Time Frame: Up to 7 days post dosing
|
Urine erythrocytes will be counted in K/uL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Urine Nitrites
Time Frame: Up to 7 days post dosing
|
Measured in mg/dL.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Prothrombin time (PT)
Time Frame: Up to 7 days post dosing
|
Measured in seconds by coagulation tests.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Activated partial thromboplastin time (APTT)
Time Frame: Up to 7 days post dosing
|
Measured in seconds by coagulation tests.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in International normalized ratio (INR)
Time Frame: Up to 7 days post dosing
|
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Fibrinogen (FIB)
Time Frame: Up to 7 days post dosing
|
Measured in mmol/L.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal change in Thrombin time (TT)
Time Frame: Up to 7 days post dosing
|
Measured in seconds by coagulation tests.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal in Feces colour
Time Frame: Up to 7 days post dosing
|
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal in Feces properties
Time Frame: Up to 7 days post dosing
|
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal in Fecal Red blood cell
Time Frame: Up to 7 days post dosing
|
Measured in Units.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal in Fecal White blood cell
Time Frame: Up to 7 days post dosing
|
Measured in Units.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Clinically significant abnormal in Fecal Occult blood
Time Frame: Up to 7 days post dosing
|
Recorded as positive or negative.
The physician will judge whether an abnormality is clinically significant.
|
Up to 7 days post dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
AUC0-72 h: Area under the plasma concentration-time curve of CBP-174 from time 0 to 72h
Time Frame: Up to 72 hours post dosing
|
Calculated by non-compartmental analysis with WinNonlin (Version 8.3.1 or above)
|
Up to 72 hours post dosing
|
AUC0-∞: Area under the plasma concentration-time curve of CBP-174 from time 0 to infinity
Time Frame: Up to 72 hours post dosing
|
Calculated by non-compartmental analysis with WinNonlin (Version 8.3.1 or above)
|
Up to 72 hours post dosing
|
Cmax: Maximum observed concentration
Time Frame: Up to 72 hours post dosing
|
Calculated by non-compartmental analysis with WinNonlin (Version 8.3.1 or above)
|
Up to 72 hours post dosing
|
Tmax: Time to maximum concentration;
Time Frame: Up to 72 hours post dosing
|
Calculated by non-compartmental analysis with WinNonlin (Version 8.3.1 or above)
|
Up to 72 hours post dosing
|
T1/2: Elimination half-life;
Time Frame: Up to 72 hours post dosing
|
Calculated by non-compartmental analysis with WinNonlin (Version 8.3.1 or above)
|
Up to 72 hours post dosing
|
λz: Terminal phase rate constant;
Time Frame: Up to 72 hours post dosing
|
Calculated by non-compartmental analysis with WinNonlin (Version 8.3.1 or above)
|
Up to 72 hours post dosing
|
CL/F: Apparent clearance;
Time Frame: Up to 72 hours post dosing
|
Calculated by non-compartmental analysis with WinNonlin (Version 8.3.1 or above)
|
Up to 72 hours post dosing
|
V/F: Apparent Volume;
Time Frame: Up to 72 hours post dosing
|
Calculated by non-compartmental analysis with WinNonlin (Version 8.3.1 or above)
|
Up to 72 hours post dosing
|
%AUCex: Percentage of AUC0-∞ obtained by extrapolation
Time Frame: Up to 72 hours post dosing
|
Calculated by non-compartmental analysis with WinNonlin (Version 8.3.1 or above)
|
Up to 72 hours post dosing
|
Collaborators and Investigators
Investigators
- Study Director: Australia Connect, Connect Biopharma Australia Pty Ltd
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CBP-174AU001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Adult Subjects
-
BiogenCompletedHealthy Adult Subjects | Healthy Elderly SubjectsUnited States
-
PfizerCompletedHealthy Adult Subjects and Healthy Elderly SubjectsBelgium
-
China Resources Biopharmaceutical Co., LtdPeking University Third HospitalRecruiting
-
Auzone Biological Technology Pty LtdCompleted
-
Mitsubishi Tanabe Pharma CorporationCompletedHealthy Adult SubjectsJapan
-
Alvotech Swiss AGIqvia Pty LtdCompletedHealthy Adult SubjectsNew Zealand, United Kingdom
-
Jiangsu HengRui Medicine Co., Ltd.Completed
-
Jiangsu HengRui Medicine Co., Ltd.CompletedHealthy Adult SubjectsChina
-
Jiangsu HengRui Medicine Co., Ltd.Completed
Clinical Trials on CBP-174
-
Suzhou Connect Biopharmaceuticals, Ltd.Active, not recruiting
-
Centre Hospitalier Universitaire DijonCompleted
-
Coherent Biopharma (Hefei) Co., Ltd.RecruitingCancer, Breast | Cancer of Pancreas | Cancer Colorectal | Cancer, Lung | Cancer of EsophagusChina, United States
-
Suzhou Connect Biopharmaceuticals, Ltd.Completed
-
Suzhou Connect Biopharmaceuticals, Ltd.CompletedModerate to Severe Ulcerative ColitisUnited States, China, Pakistan, Ukraine
-
Suzhou Connect Biopharmaceuticals, Ltd.Tigermed Consulting Co., Ltd; Nucleus Network LtdCompleted
-
Suzhou Connect Biopharmaceuticals, Ltd.TerminatedChronic Rhinosinusitis With Nasal PolypsUnited States, China, Poland, Spain, Ukraine
-
Coherent Biopharma (Suzhou) Co., Ltd.Recruiting
-
Coherent Biopharma (Suzhou) Co., Ltd.Recruiting
-
Taipei Veterans General Hospital, TaiwanUnknown